Egetis Therapeutics AB announced the appointment of Karl Hård, PhD, as Head of Investor Relations and Communication, effective February 1. Karl will be a member of the Company's leadership team and report to the CEO Nicklas Westerholm. Karl has over 25 years of experience in the global pharmaceutical industry having worked for almost 20 years at AstraZeneca and thereafter at biotechnology companies and a strategic communications consultancy firm. Prior to joining Egetis Karl was Head of Investor Relations at Redx Pharma in the UK.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.305 SEK | -9.41% | +25.15% | +13.26% |
06-20 | Transcript : Egetis Therapeutics AB - Special Call | |
06-19 | Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.26% | 193M | |
+20.03% | 126B | |
+23.61% | 117B | |
+22.79% | 27.52B | |
-18.07% | 20.87B | |
-14.15% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |
- Stock Market
- Equities
- EGTX Stock
- News Egetis Therapeutics AB
- Egetis Therapeutics Appoints Karl Hård as Head of Investor Relations and Communication, Effective February 1, 2022